Skip to content
Biodatica
Start free

Chugai Pharmaceutical

Gilbert, Arizona

OncologyPhase IListed · CHGCY

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase I trial registered: Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

2d agoTrial registeredJul 17, 2026Source filing (opens the source filing in a new tab)

Momentum

89no change

Momentum 89 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Jul 31, 2026

    ALK Positive Non-small Cell Lung Cancer · NOT_YET_RECRUITING · sponsor: Chugai Pharmaceutical · AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

    ClinicalTrials.gov · NCT07617337 (opens the source filing in a new tab)

  2. Trial

    PHASE1 registered

    Oct 8, 2025

    Extensive Stage Small Cell Lung Cancer · RECRUITING · sponsor: Chugai Pharmaceutical · A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

    ClinicalTrials.gov · NCT07107490 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Dec 9, 2024

    Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM), Immune-mediated Necrotizing Myopathy (IMNM), Immune Thrombocytopenia (ITP) · ENROLLING_BY_INVITATION · sponsor: Chugai Pharmaceutical · Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)

    ClinicalTrials.gov · NCT06723106 (opens the source filing in a new tab)

  4. Trial

    PHASE1 registered

    Apr 17, 2023

    Solid Tumor · COMPLETED · sponsor: Chugai Pharmaceutical · A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

    ClinicalTrials.gov · NCT05735366 (opens the source filing in a new tab)

  5. Trial

    PHASE1 registered

    Sep 10, 2020

    Locally Advanced or Metastatic Solid Tumors · ACTIVE_NOT_RECRUITING · sponsor: Chugai Pharmaceutical · A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

    ClinicalTrials.gov · NCT04511845 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources